Archive for the ‘china retractions’ Category
A team of chemists at Hunan University and Zhejiang Shuyang Chemical Company in China have retracted a paper from the Journal of Chemical & Engineering Data after “inconsistencies with the literature” led them to discover “errors” in the way the data were reported.
Wang then went through the original notes with the first author, and realized that the data reported in the paper didn’t match the experimental results. The lab then conducted further experiments, and discovered that multiple corrections would be necessary. They were, as Wang told us: Read the rest of this entry »
The editor of the Journal of Medical Case Reports, a BioMed Central title, has retracted and removed a case study of a novel surgical treatment after the patient’s legal guardian withdrew consent post-publication.
The paper, “Novel two-stage surgical treatment for Cantrell syndrome complicated by severe pulmonary hypertension: a case report,” describes the treatment of a six-month-old Han Chinese girl suffering from a rare combination of birth defects called Cantrell syndrome, complicated by pulmonary hypertension.
The original article, published in March 2014, has been removed from the journal’s website, though the abstract can be read on PubMed. It is unclear whether the authors, the child’s guardian, or some other party informed the editor of the withdrawal of consent.
The brief notice offers few details:
Yihang Shen published a paper using his PhD research on the molecular biology of fetal rodent livers earlier this year in DNA and Cell Biology. Unfortunately, he didn’t have permission to publish the data. He also omitted the names of people who participated in the research, and listed an incorrect funding source.
The “cited grant,” according to the journal editor, was a grant awarded to Richard Finnell, a UT Austin researcher who often works with Shen’s PhD advisor at Shanghai Jiao Tong University, the well-known geneticist Fanyi Zeng.
Earlier this year, we reported on the retraction of a paper because of sloppy work by an outside lab. Now, we have the story of a retraction for “negligence” by a translator. Specifically, the author says the passages shared between the retracted 2015 vascular paper and another paper in EMBO Journal are a result of “negligence on the part of the translation company that I trusted to make my manuscript ready for submission.”
Some of the figures were also reused between the two articles, both in Biochimica et Biophysica Acta General Subjects.
The articles both tested the cancer-fighting properties of a derivative of the active compound present in Boswellia serrata gum resin.
Chemists at Lanzhou University in China did the right thing last month, retracting a paper in Advanced Synthesis & Catalysis because of issues with a reactant that could only be corrected by changing “all the text and quantities.”
When the scientists were adding what was labeled Reactant 1 to the mix, they believed it was α-ethoxycarbonyl-α-azido-N-phenylacetamides. Unfortunately, what they were actually using was a decomposed version of the molecule, which threw everything off.
A paper whose expression of concern we covered in November 2014 has been retracted and republished “because of the extent of the changes necessary,” according to the Lancet Respiratory Medicine.
This study was a meta-analysis of research on how the timing of tracheostomies — placing a breathing tube directly into the windpipe — affects patients’ mortality rate. The original paper found that critically ill patients who received a tracheostomy earlier fared better than those for whom the procedure was delayed for weeks after intubation, the recommended practice.
However, when the authors calculated how many patients died, they assumed that any patient who wasn’t discharged from the intensive care unit (ICU) had died there, instead of looking for other explanations. This made their estimates unreliable.
The publisher convened a panel, which ultimately decided retraction and republication was the most appropriate course of action.
The authors of a 2014 paper in The Scientific World Journal on rock slopes have retracted their article for “erroneous” data.
The paper, “Slope Stability Analysis Using Limit Equilibrium Method in Nonlinear Criterion,” came from a group of researchers from institutions including the Changjiang River Scientific Research Institute in Wuhan, and the Key Laboratory of Transportation Tunnel Engineering at Southwest Jiaotong University in Chengdu. It’s about (we think) how to calculate the safety of rock slopes, and how vulnerable they are to landslides.
Here’s the notice, which as a pretty fair ratio of words to information:
A group of researchers in China and the United States have retracted a 2014 paper in the Journal of Cardiovascular Pharmacology after discovering the data were fatally flawed.
The article examined whether the anti-arrhythmia drug zacopride affected cardiac remodeling after heart attack, and came from Bo-We Wu, of Shanxi Medical University, in Taiyuan, and colleagues, including one author from Savannah, Georgia.
Here’s more from the notice for “Activation of IK1 channel by zacopride attenuates left ventricular remodeling in rats with myocardial infarction”:
The Journal of Materials Chemistry B has issued a laundry list of corrections for a 2014 chemotherapy paper, which address re-use of “some text”, incorrectly stated doses, and miscalculations of the drug concentration, among other issues.
The paper described a new way to deliver gemcitabine via nanoparticles, focusing the drug on the tumors.
It turns out the authors’ focus wasn’t so clear when writing the paper. The researchers, at the Chinese Academy of Medical Science, Peking Union Medical College, and Tianjin University in China, said they used “some text” from two 2013 papers by a team of French oncologists “without appropriate attribution,” as well as repeatedly getting the in vivo dose wrong. The manuscript also contained several incorrect calculations of the “drug loading,” or the proportion of active drug.
Here’s the correction for “Tailor-made gemcitabine prodrug nanoparticles from well-defined drug–polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy” (free, but requires sign-in): Read the rest of this entry »